Project Grant R01CA296810
Award Date
1/1/25
Completion Date
12/31/29
Dollars Obligated
$635K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 in funding to Aakha Biologics, Inc. to develop a novel first-in-class bispecific antibody therapy for the treatment of advanced metastatic lung cancer. The bispecific antibody targets both MICA/B, which is cleaved from cancer cell surfaces leading to immune evasion, and mesothelin (MSLN), a tumor-associated antigen. This combination aims to block MICA/B shedding and enhance...
This $154,400 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research by the Broad Institute, Inc. in Cambridge, MA to investigate the activation and dimerization of the SLFN12 RNase enzyme as a potential new cancer therapy. The key objectives are to:
Determine if high SLFN12 expression alone can induce cytotoxicity through degradation of the tRNA-Leu-TAA substrate.
Assess whether a mutation at the SLFN12 homodimer interface...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $249,645 to Boston Children's Hospital to develop a novel cancer immunotherapy strategy using genetically engineered B cells. The research aims to exploit homology-driven gene editing to generate tumor-specific B cells that can directly kill cancer cells and trigger robust anti-tumor T cell immunity. The project will evaluate the efficacy and tolerability of this B cell-based...
This Project Grant award, valued at $362,741 and funded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research to develop and evaluate a novel combination therapy using a small nanocarrier to deliver a PARP inhibitor (BMN673) and a DNA methylation inhibitor (5-azacytidine) for the treatment of non-small cell lung cancer.
The key objectives of this 5-year project are to: 1) optimize the formulation of the BMN673/5-azacytidine...
This federal Project Grant award from the National Cancer Institute (under CFDA 93.395 - Cancer Treatment Research) provides $513,859 to the Dana-Farber Cancer Institute, Inc. in Boston, MA to develop a novel platform for persistent adoptive cellular therapy using hematopoietic stem cell (HSC)-derived chimeric antigen receptor (CAR)-expressing natural killer (NK) cells. The project aims to leverage naturally occurring NK-specific regulatory elements to restrict CAR expression to the NK cell...
This $450,429 Project Grant award from the National Cancer Institute (NCI), part of the National Institutes of Health, supports research to advance immunotherapy for non-small cell lung cancer (NSCLC) by targeting the MUC1-C protein. The goal is to identify novel therapeutic strategies using anti-MUC1-C antibody-drug conjugates (ADCs) alone and in combination with immune checkpoint inhibitors (ICIs) to enhance anti-tumor immunity and restrain NSCLC progression, particularly for EGFR-mutant...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is focused on developing a novel cancer therapy that combines bacterial toxins to target lung cancers expressing high levels of the sialyl Lewis X (sLeX) glycan. The $378,675 award, spanning June 2024 to May 2026, will be used by Louisiana State University to engineer and characterize a fusion protein called SSL11-PE24. This fusion protein is designed to bind to sLeX, which is overexpressed...
The National Cancer Institute (NCI) awarded Duke University a $602,881 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop novel immunotherapies using optimized tumor cell-penetrating antibodies. The goal is to translate these antibody-based therapies into the clinic to effectively combat aggressive, mutation-driven cancers, including those that have become resistant to small molecule inhibitors. The key products/services to be delivered include:
Elucidating the...
This $3,000,000 project grant awarded by the National Science Foundation (NSF) Engineering program (CFDA 47.041) will address a decades-long challenge in the field of ribonucleic acid (RNA) technology. The project, titled "TRAILBLAZER: SOLVING THE GRAND SELF-AMPLIFYING RNA (SARNA) CHALLENGE," aims to develop modified self-amplifying RNA (SARNA) that can last longer inside cells, which will advance RNA engineering capabilities across diverse industries from farming to medicine.
The...
The National Cancer Institute awarded a $407,113 Project Grant (CFDA 93.396 - Cancer Biology Research) to Trustees of Boston University for the development of bio-orthogonal mid-infrared photothermal imaging technology to study cancer metabolism. This 3-year award, running from September 1, 2024 to August 31, 2027, aims to: 1) build a library of nitrile-based probes to sense molecular events in cancer cells; 2) develop nitrile-tagged small molecules to measure nutrient metabolism; and 3)...